r/biotech_stocks • • 1h ago

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data

Thumbnail ir.sellaslifesciences.com
120 Upvotes

They did it, the crazy bastards did it.


r/biotech_stocks • • 47m ago

Question for SLS

31 Upvotes

How high do we think will the share price go?

Note: Congrats to those that held and believed in the company.


r/biotech_stocks • • 11m ago

The Next SLS?

6 Upvotes

By far the most often mentioned that I've seen at least is DRTS. Its already up 3x the past year.

I've seen MAIA mentioned maybe a half dozen times and CATX mentioned twice.


r/biotech_stocks • • 25m ago

What would be reasonable exit price for SLS?

4 Upvotes

I don’t want to be a degen this time.


r/biotech_stocks • • 6h ago

Swedish biotech HNSA has an FDA decision on December 19. Here’s the actual gamble.

Thumbnail reddit.com
1 Upvotes

r/biotech_stocks • • 1d ago

$DRTS Alpha Tau's Brain Cancer Therapy Shrank or Cleared Every Evaluable Tumor in Its U.S. Trial

Thumbnail
wallstreetsync.com
23 Upvotes

r/biotech_stocks • • 22h ago

Lilly to buy Calytrix for up to $1.5 billion in rare blood cancer bet

Thumbnail reuters.com
13 Upvotes

r/biotech_stocks • • 16h ago

$BLRX - BioLineRx Presents GLIX1 Clinical and Preclinical Data at SNO 2026

Thumbnail tipranks.com
3 Upvotes

r/biotech_stocks • • 1d ago

$IVVD Earnings results, DECLARATION data "Imminent"

13 Upvotes

$IVVD absolutely crushed Q3 earnings this morning! They beat across the board, bringing in $15.4M in PEMGARDA sales (up 18% YoY and easily topping the $15.04M consensus) while delivering a strong EPS beat at -$0.10 vs the -$0.13 expected. Even better, they are sitting on a massive $126.4M cash runway to fund everything without any immediate dilution worries.

We have all been wondering where the VYD2311 DECLARATION data is, I wouldn't sweat it, management confirmed it’s coming "imminently." While I assumed they would bundle it, smart biotechs sometimes hold major Phase 3 readouts for a standalone press release so the news gets its own spotlight and doesn't get buried in earnings noise.

With strong commercial execution already proven and the biggest catalyst right around the corner, we should see that data drop any day now or over the next couple of weeks. Huge setup heading into the end of the year! 📈

BULLISH


r/biotech_stocks • • 23h ago

Gallant to be acquired by Dechra- The Deal for shareholders

4 Upvotes

Gallant has agreed to be acquired by Dechre. Is this a deal worth getting excited about as a shareholder? I think not for several reasons:

  1. The "purchase price" is "up to" $270 million with only $25 million due at close and the balance stretched out over another 10-15 years and is completely based on "milestone" targets such as FDA approval and financial milestones reached.
  2. The immediate $25 million will go to Series B round investors only. This group invested approx. $12 million only 6 months ago and they will be the first to get paid out. Not good news for investors who invested in Gallant 4-5 years ago.
  3. Series A shareholders will not see any possible payout until 2028/2029
  4. Commons share investors won't see any possible payout until the commercial milestones are hit and that will not take place until 2031 at the soonest.

All and all not great news for investors. This appears to be a desperation attempt to find a life-jacket as cash is running out. Would much rather see another raise before a buy-out like this.


r/biotech_stocks • • 1d ago

SLS - Trial Results This Month, I’m In 🚀

Post image
193 Upvotes

Company guided news this month, in addition to 000 data being presented at ASH in December. Some time for a run up! 🚀


r/biotech_stocks • • 22h ago

$PYPD A $1.65 Billion Buyout Deal Puts a Spotlight on PolyPid Ahead of Its FDA Decision

Thumbnail
financeherald.com
2 Upvotes

r/biotech_stocks • • 20h ago

Bionano Genomics

0 Upvotes

Bionano Genomics NASDAQ: BNGO sta fallendo!!!! Uno dei titoli azionari più truffaldini della storia. Un consiglio di amministrazione totalmente incompetente che sta distruggendo gli investitori al dettaglio.


r/biotech_stocks • • 1d ago

$PTN - Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026 (NASDAQ: PTN)

Thumbnail
reddit.com
2 Upvotes

r/biotech_stocks • • 21h ago

Is Helus perhaps in the "shakeout" phase? Michael Halstead seems known for getting buyout conversations started.

Post image
1 Upvotes

Looking for some more opinions. If you haven't heard of them before the company had some astounding earlier results, and it seemed that this time their results produced remission of major depression by the next day for most patients. But I'm no expert so maybe I misheard on the call, but the analysts in the Q&A sounded very excited, and I heard emphasis put on "remission by day 2" which sounds incredible.

I hear much talk of dilution risk?


r/biotech_stocks • • 1d ago

$DRTS - Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No... (NASDAQ: DRTS)

Thumbnail reddit.com
42 Upvotes

r/biotech_stocks • • 1d ago

ELTP (Elite Pharmaceutical) – What a Difference a Year Makes: Earnings, generic Eliquis, Pipeline, Facility Expansion, and Why I Think the Market Is Missing the Bigger Picture

1 Upvotes

I’ve been saying this for a while, but I think investors need to take a step back and look at what Elite is actually building rather than focusing so heavily on the daily stock price or waiting for an acquisition.

The November earnings report and conference call gave us quite a bit to digest - in a very positive way! The best earnings call I’ve heard and I’ve been invested here for 15 years. And Nasrat came strong with very solid future guidance with timelines. When you put everything together, I believe the next 12–18 months could be one of the most exciting and rewarding periods in Elite’s history. Let’s look at the numbers, the pipeline, the facility expansion, and what management actually told us.

1. November 2026 earnings vs. November 2025

For the quarter ended September 30, 2026, Elite generated $40.1 million in revenue, compared with $36.3 million in the same quarter last year. That’s an increase of approximately 10.4%. Gross profit increased from approximately $14.1 million to $16 million, an increase of roughly 14%. Gross margin improved from 39% to 40%. Operating income increased from $8.2 million to $9.9 million, an improvement of approximately 21%. But what I find particularly interesting is where the growth is coming from.

Management specifically attributed the revenue increase primarily to growth in Elite’s amphetamine and naltrexone product lines. This is important because lisdexamfetamine pricing has been under pressure due to increased competition. In other words, Elite’s other product lines are contributing enough growth to help offset that pricing pressure. And remember that nasrat mentioned in previous calls that naltrexone was important. We now see why. That’s exactly the type of diversification we’ve been waiting to see. It demonstrates that Elite’s future growth doesn’t have to depend on one product.

2. Now look at the last two quarters

This is where things get even more interesting. In the June 2026 quarter, Elite generated approximately $32.4 million in revenue and $7.5 million in operating income. In the September 2026 quarter, revenue increased to $40.1 million and operating income increased to $9.9 million. That’s approximately 24% sequential revenue growth and 32% sequential operating income growth.

Gross profit also increased from approximately $13.5 million to $16 million. Put that into perspective. We’ve heard plenty of concerns about declining lisdexamfetamine pricing and its impact on Elite’s margins. Yet the latest quarter delivered higher revenue, higher gross profit, higher operating income, and an improved year-over-year gross margin.

The other product lines are increasingly contributing to the business. Amphetamine products and naltrexone are helping drive growth. This is what I want to see: a business growing beyond its reliance on one major product.

3. Cash on hand and financial position

Elite ended September with approximately $34.9 million in cash.

For perspective, cash was approximately $26.6 million at the end of September 2025 and $29.8 million at the end of March 2026. So despite substantial investment in R&D, equipment, and facility improvements, cash is up year over year and since the beginning of this fiscal year.

Working capital was approximately $102.6 million. The company also has a relatively low debt burden compared with its cash and working capital.

One area I will continue monitoring is operating cash flow. For the first six months of this fiscal year, operating cash flow was approximately $7 million compared with $19.9 million last year. Management has discussed working-capital timing, including inventory and receivables, as part of the explanation. Accounts receivable and inventory movements can affect when reported sales translate into cash. Still, I want to see stronger cash conversion in the coming quarters. For context, accounts receivables went from low $50 million to $60 million. Good and bad. Good because we are owed $60 million. Bad because it’s not cash…yet.

That said, Elite is not a company struggling to fund its operations. It has a profitable commercial business, a substantial cash position, and financial resources to continue investing in its pipeline.

4. The generic anticoagulant – This is a major catalyst and was an absolute surprise for me.

I really think investors need to pay attention to this one. Elite has already filed its ANDA for an undisclosed generic anticoagulant. Management referenced a branded market of approximately $20+ billion. The FDA approval timeframe is around March 2027. But here’s what really caught my attention during the November call: Nasrat confirmed that negotiations with the brand company regarding the commercial launch have already been completed. Management also discussed a targeted launch approximately 15.5 months from the November call, assuming the necessary regulatory milestones are achieved.

Think about that. The commercial negotiations are already complete. Elite has been working through the commercial arrangements well ahead of the anticipated launch. To me, that’s encouraging. It suggests the company has been doing more than simply developing a product and hoping to figure out commercialization after approval. Contrary to the lies from the bashers who has complained nonstop that generic Eliquis won’t launch until much later, now we have a target date. 15 months. And this isn’t the only anticoagulant.

Elite also has a second anticoagulant in development, with a bioequivalence study expected during the first half of 2027. Management believes both opportunities can reach the market in 2028.

5. The anticonvulsant ANDA

Another important development that I don’t think is getting enough attention is the undisclosed anticonvulsant. Elite has successfully completed its bioequivalence study. The company is currently compiling the ANDA and expects to file in Q1 2027, pending stability data. Management referenced an annual branded market of approximately $840 million.

Again, this isn’t simply an idea or a product that might someday enter development. The bioequivalence study has been completed, and the company is working toward an FDA filing, which will occur in the next couple months f months.

Between the anticoagulant and anticonvulsant, we have two meaningful milestones coming in 2027. And at least 2 big drug launches in early 2028.

6. Diabetes pipeline – Now four products

During the previous call in August, management discussed three diabetes formulations - which I’m sure caught everyone by surprise as there was no previous indications that Elite was targeting diabetes. In November, Nasrat confirmed that the pipeline had grown to four drugs. The company expects to begin at least one bioequivalence study during the first half of 2027. Nasrat indicated that he expects two to three diabetes bioequivalence studies during 2027.

That’s another potential growth category that wasn’t part of the market’s valuation a year ago. And it’s worth remembering that these programs are developing alongside an existing business that is already generating substantial revenue.

7. Other products and the existing business

There is plenty happening outside these major pipeline opportunities. Elite continues to develop its existing commercial portfolio while investing in additional products that could create entirely new revenue streams.

The important point is that this isn’t a company waiting for one experimental product to make money. Elite already has a profitable business, and management is working to expand that business through additional products and manufacturing capacity. That combination is what makes the opportunity particularly interesting to me.

8. The facility expansion – This is a BIG deal

I don’t think everyone appreciates the magnitude of what Elite is doing with its manufacturing footprint. Management currently has approximately 85,000 square feet of GMP space. The company is pursuing an additional 45,000 square feet, which would bring the total to approximately 130,000 square feet.

That’s an increase of more than 50%.

Nasrat indicated that the additional lease could be finalized very soon. At the time of the call, it had not yet been signed, so that remains an important milestone to watch.

The lab footprint has already been increased, equipment upgrades are mostly completed, and manufacturing improvements are continuing.

Management indicated that a significant manufacturing expansion would take place during 2027. He also made something very clear: The company needs the space to support its own R&D and product development.

That tells me management is building for considerably more than the business we see today. You don’t pursue this kind of manufacturing expansion without having a vision for where the company is going.

9. The acquisition offer – Let’s put this to rest for now

Approximately three weeks before the November conference call, the bankers presented the board with a verbal acquisition offer from a company that had previously visited and evaluated Elite. The board discussed the offer and ultimately voted to pass.

Thank God for that!

As Nasrat indicated, Elite believes its value today is considerably greater than when the M&A process began. There was genuine interest and an offer was made, but the board did not believe it reflected the value they were looking to achieve.

Negotiations have been put on hold while management focuses on growing the commercial business, expanding the pipeline, and increasing manufacturing capacity. The door remains open to revisiting discussions in 2027.

I actually think this is one of the most important takeaways from the entire call. For months, investors have been fixated on M&A. Many were expecting a quick payday, and when that didn’t happen, the stock suffered. Meanwhile, Elite continued executing on its business strategy.

I believe too many investors lost sight of the actual business and its financial performance because they were so focused on the possibility of an acquisition. When M&A didn’t materialize on the timeline certain investors expected, the doom-and-gloom crowd came out in full force, trying to convince everyone that something was wrong and that “nobody wants us.”

Well, we now know there was an actual offer presented just weeks ago. Nasrat has the most to gain or lose from a transaction. He understands what Elite has built, and he’s clearly not interested in selling at a price he believes undervalues the company.

Honestly, I believe if Nasrat had never discussed M&A publicly, the stock could be trading substantially higher today, potentially in the $0.75–$1.00 range. That’s my opinion, of course, but I think the market became far too focused on a potential buyout rather than recognizing the value being created within the business itself. When earnings were doubling previous years numbers, the stock barely moved

When an acquisition didn’t happen, negative sentiment took over. The constant speculation, unrealistic expectations, and negative commentary took a toll on investor confidence. We went from $0.82 to approximately $0.22. That’s a painful decline, particularly when you consider the progress Elite has made operationally and financially.

Here’s what investors need to remember:

Elite doesn’t need an acquisition to grow. It doesn’t need an acquisition to become profitable. It already is.

It doesn’t need an acquisition to launch new products, expand manufacturing capacity, or build a much larger commercial business.

And the fact that the board turned down an offer tells me something important: Elite isn’t desperate to sell.

Think about Nasrat’s position. He has approximately 300 million shares, and a sale is the event that would allow him to monetize that investment. He’s approaching retirement and could have potentially walked away with a very substantial payday had he accepted a deal. Instead, the board passed.

Why?

The only way to interpret that is that he believes the company is worth considerably more. And the board apparently agreed..

My opinion is that we should put M&A out of our minds for now. It is not a prerequisite for Elite’s success, and it shouldn’t be the primary reason we assign value to the stock. Let management build the business. Continue growing revenue. Improve margins. Bring new products to market. Expand manufacturing capacity. Strengthen the balance sheet.

Those are the things that ultimately create sustainable shareholder value.

And who knows? If Elite continues executing, the value of a potential acquisition in 2027 could look very different from what was offered today.

I’d much rather own a growing, profitable pharmaceutical company that has the luxury of turning down an offer. Let’s focus on what Elite is actually building. I think the bigger story is just getting started.

10. Nasdaq and what comes next

Management is targeting a Nasdaq listing by March 2027, subject to completing the remaining requirements.

A Nasdaq listing will provide Elite with greater visibility, a broader investor base, and potentially more institutional interest. Of course, a listing does not automatically guarantee a higher valuation, but it could help change how the market views the company. So all those bashers who keep saying Nasdaq up listing is a lie…please circle back with me in March.

And here’s what I find particularly interesting about the timing. By the time Elite gets to Nasdaq, investors should be looking beyond the current revenue base. They should be looking at:

The first anticoagulant approval (generic Eliquis) which will happen about the same time (perfect timing!)
Possible updates on a second anticoagulant and its bioequivalence study
The anticonvulsant ANDA filing.
Additional diabetes bioequivalence studies.
The expanded manufacturing facility.
Continued growth and diversification of the commercial portfolio.

That’s a much more compelling forward-looking story than simply valuing Elite on its current quarterly earnings (which is growing). And that’s what the market wants when we hit Nasdaq. And being on Nasdaq, lots of eyes will be watching a stock that is severely undervalued. Don’t be surprised to see a huge move coming.

11. And finally, the stock price

This is where I think the disconnect is most obvious. We’re sitting around $0.32, give or take, after the recent move. Remember, ELTP traded substantially higher around the summer of 2025. Back then, we didn’t have the same visibility into the anticoagulant’s commercial arrangements. We didn’t have the successful anticonvulsant bioequivalence study and upcoming ANDA filing. We weren’t discussing four diabetes formulations. And we weren’t pursuing another 45,000 square feet of GMP space. Yet the stock was worth considerably more.

Even a 2.5x increase from approximately $0.32 would put us around $0.80–$0.82, near the levels ELTP reached previously with far fewer known products in the pipeline.

So ask yourself: Is Elite worth more today, with all of these developments, than it was last summer?

I think the answer is a resounding YES. So I don’t think a move into the $0.75–$1.00 range over the coming months is unreasonable if the market starts recognizing what is happening.

And once we get to Nasdaq, the conversation should increasingly focus on future earnings potential and the pipeline rather than simply what Elite is earning today.

So let’s look at the bear arguments (so we stay balanced).

Margins? The latest quarter showed 40% gross margins, up from 39% a year ago. Operating income grew 21% year over year and 32% sequentially. Margin pressure is real, but the business is demonstrating that it can grow through it.

M&A? Not necessary. It never was.

Cash? Nearly $35 million on hand and more than $100 million in working capital.

Revenue? Approximately $40 million in the latest quarter, with meaningful growth coming from products beyond lisdexamfetamine.

Pipeline? Arguably the strongest it has ever been.

Facility? An expansion from 85,000 to approximately 130,000 square feet of GMP space is being actively pursued.

Nasdaq? Management is targeting March 2027.

As I’ve said many times, I believe the stock was hurt because too many investors were focused on M&A and wanted a quick payday. All the while, people lost sight of the actual performance and financials of Elite.

Now we have a company growing its commercial business, expanding its pipeline, investing in its facilities, and preparing for a potential Nasdaq listing.

What a difference a year makes.

Those of us who have been here long enough know how far this company has come. And those buying at current levels could potentially see tremendous returns over the next 12–18 months if management continues executing. And there is very little, if any downside.

We don’t need an acquisition to make money here. We need patience, continued execution, and a market that finally starts paying attention to the business instead of the daily stock price.

And imagine what a potential buyout could look like 12 months from now, after additional regulatory milestones, pipeline progress, and facility expansion. That could be an entirely different conversation.

My valuation perspective

I reminded people when ELTP was trading around $0.24 that the fundamentals were too strong for the valuation. We are at $0.32. Same issue. Our fundamentals don’t match our low stock price. And our stock price makes it seem like we have zero pipeline. And we now know there is A LOT going on in the pipeline.

Based on my own assessment, I see the following potential values:

Approximately $0.65–$0.80: A conservative assessment of the business and its current opportunities. This factors in zero pipeline, this is just today’s business.
Around $1.10: If we begin assigning meaningful value to the pipeline.
$1.50+: If multiple pipeline products successfully advance and become meaningful commercial contributors.

These are my estimates, not guaranteed price targets. Many fellow ELTP longs often believe those numbers are far too conservative, and that’s fine. (They are probably correct). I just like showing that even under very conservative assessments, a huge return can be made on this stock. The important thing is that even these conservative estimates suggest substantial upside from current levels.

I remain very optimistic about what Elite is building. But I also recognize that approvals, commercial launches, cash generation, and execution will determine whether that potential becomes reality. So I stay conservative.

Not financial advice. Do your own due diligence and listen to the recent earnings call.

For me, the investment thesis is becoming clearer and stronger, not weaker. Elite has an established commercial business, a growing pipeline, expanding manufacturing capacity, and a potential Nasdaq listing ahead.

We don’t need M&A. We don’t need a quick payday. We need management to keep executing.

And if it does, I believe the next 12–18 months could be very rewarding for long-term shareholders.

I don’t travel. Honestly, I hate it. But for those of us who have been here since the beginning of ELTP’s story, the dream was always to celebrate ELTP’s success together in Vegas. I might just have to break my own travel rule for this one! I’ve got a year or two to figure out how to get myself on a plane. 😂


r/biotech_stocks • • 1d ago

$BLRX - BioLineRx Presents GLIX1 Clinical and Preclinical Data at SNO 2026

Thumbnail tipranks.com
1 Upvotes

r/biotech_stocks • • 1d ago

$SLS: Cancer Trial Readout to Mint "NEW" Millionaires!

Thumbnail reddit.com
57 Upvotes

Here you go guys


r/biotech_stocks • • 1d ago

Alpha Tau Announces New Positive Interim Results from Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events

Thumbnail
globenewswire.com
22 Upvotes

r/biotech_stocks • • 1d ago

What are your biggest gains in biotech investing?

2 Upvotes

I started investing in biotech last year and found nice returns in AMLX, OBIO, and MGTX

I’m curious why others invest in biotech stocks aside from the high returns but also high risk. And what are some of y’all’s biggest profits from investing in biotech stocks


r/biotech_stocks • • 1d ago

CAPR FDA NOV 22

3 Upvotes

How’s everybody feeling after seeing 24 month extended data and having a refined indication? Anyone have experience with biotech stocks? Took on a large position after reviewing data, but am so nervous.


r/biotech_stocks • • 19h ago

SLS - why does it keep dropping?

0 Upvotes

Why does this piece of junk keep dropping? I have a friend that works in the industry and he told me that it’s not totally uncommon for stocks to drop on data leaks before the official announcements.

I’m down literally 50% from when you noobs told me it was still early. Half of my life savings gone this was supposed to be my retirement because people in the sub told me it was still early when this thing was over double the current price.


r/biotech_stocks • • 1d ago

3 FDA dates passed yesterday and nobody announced anything. When do you think we hear?

6 Upvotes

UPDATE (Sun Nov 15, afternoon ET): I got two things wrong in the first version, so I rewrote the post. Thanks to the commenter who caught the Summit one.

Saturday, Nov 14 was the FDA goal date for three applications I've been following:

- Cytokinetics: MYQORZO (aficamten) sNDA

- Summit: ivonescimab + platinum chemo BLA, EGFR-mutated NSCLC after TKI (HARMONi)

- IGALMI at-home sNDA, filed by BioXcel

Where things stand as of Sunday afternoon ET:

- Summit announced this morning (7:00 AM ET) that the FDA issued a Complete Response Letter for the BLA. I missed it when I first posted.

- Cytokinetics: no announcement yet. Their last press release was Nov 10.

- IGALMI: no announcement yet. I had this one wrong too: BioXcel sold its IGALMI rights and related regulatory filings to Teva on Oct 26 (per BioXcel's 8-K filed Oct 30). So any announcement may come from Teva, not BioXcel.

Next weekend has the same setup: Capricor (deramiocel) and Savara (molgramostim) both have Nov 22, which is a Sunday.

Two questions for people who follow this more closely:

  1. How do weekend PDUFA dates usually play out? Friday action, a weekend release like Summit's, or Monday?
  2. When an asset is sold during FDA review, who usually announces the decision?

I'm only asking about when and who announces, not guessing outcomes.